Новый препарат OLN324 показал эффективность не хуже фаримума при лечении диабетической макулярной отёчности

VEGF/Ang-2 inhibitor ‘potentially exciting development’ in diabetic macular edema Sunir J. Garg, MD, FACS, FASRS, discussed findings from a proof-of-concept clinical trial comparing OLN324, a bispecific antibody targeting VEGF and Ang-2, with faricimab in patients with diabetic macular edema in this video with Healio. The results were presented at the American Society of Retina Specialists annual meeting. OLN324 (Ollin Biosciences) demonstrated rapid drying of the macula that was “at least comparable, if not better,” than that seen with Vabysmo (faricimab, Genentech), according to Garg, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at Thomas Jefferson University. At week 12, more patients who received OLN324 had resolution of fluid vs. those who received faricimab, and patients had similar visual acuity results with OLN324 vs. faricimab, Garg said. “This is a potentially exciting development. It’s a short-term study on just a few eyes so there’s a lot more work to do, but there’s still a lot of innovation and improvement to be had even with drugs that we’re already familiar with,” he said. “It’s an exciting time for us to be retina specialists for all that we’re able to do for our patients with diabetes.”